The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 14, 2010.

A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001:

1. GLAASS Financial, LLC; to become a bank holding company through the acquisition of 36.4 percent of the voting shares of EMSWATER Financial, LLC, both in Exeter, Nebraska. In connection with this application, Applicant also has applied to acquire EMSWATER Financial, LLC and First National Insurance Agency, Inc., both of Exeter, Nebraska pursuant to section 225.28(b)(11)(A) of Regulation Y.

Board of Governors of the Federal Reserve System, September 16, 2010.

# Robert deV. Frierson,

Deputy Secretary of the Board. [FR Doc. 2010–23522 Filed 9–20–10; 8:45 am] BILLING CODE 6210–01–S

# FEDERAL RESERVE SYSTEM

# Government in the Sunshine Act Meeting Notice

**AGENCY HOLDING THE MEETING:** Board of Governors of the Federal Reserve System.

TIME AND DATE: 12 p.m., Monday, September 20, 2010.

The business of the Board requires that this meeting be held with less than one week's advance notice to the public, and no earlier announcement of the meeting was practicable. **PLACE:** Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW., Washington, DC 20551. **STATUS:** Closed.

### **Matters To Be Considered**

1. Implications of Dodd-Frank Reform Act for Board Organization and Staffing. FOR MORE INFORMATION PLEASE CONTACT: Michelle Smith, Director, or Dave Skidmore, Assistant to the Board, Office of Board Members at 202-452-2955. **SUPPLEMENTARY INFORMATION:** You may call 202-452-3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at http:// www.federalreserve.gov for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: September 17, 2010.

### Robert deV. Frierson,

 $\label{eq:Deputy Secretary of the Board.} \\ [\text{FR Doc. 2010-23669 Filed 9-17-10; 4:15 pm}]$ 

BILLING CODE 6210-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Guidance on Withdrawal of Subjects From Research: Data Retention and Other Related Issues

**AGENCY:** Office for Human Research Protections, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** The Office for Human Research Protections (OHRP), within the Office of the Assistant Secretary for Health, is announcing the availability of a guidance document entitled, "Guidance on Withdrawal of Subjects From Research: Data Retention and Other Related Issues." The guidance document provides OHRP's first formal guidance on this topic. The document, which is available on the OHRP Web site at http://www.hhs.gov/ohrp/policy/ subjectwithdrawal.html or http:// www.hhs.gov/ohrp/policy/ subjectwithdrawal.pdf, is intended primarily for institutional review boards (IRBs), investigators, and funding agencies that may be responsible for the review or oversight of human subject research conducted or supported by the Department of Health and Human Services (HHS). The guidance document announced in this notice finalizes the draft guidance entitled, "Guidance on Important Considerations for When Participation of Human Subjects in Research is Discontinued," that was made available for public comment through a notice in the **Federal Register** on December 1, 2008 (73 FR 72804). OHRP received comments on the draft guidance document from 30 individuals and organizations, and those comments were considered as the guidance was finalized.

**DATES:** Comments on OHRP guidance documents are welcome at any time.

ADDRESSES: Submit written requests for a single copy of the guidance document entitled, "Guidance on Withdrawal of Subjects From Research: Data Retention and Other Related Issues," to the Division of Policy and Assurances, Office for Human Research Protections, 1101 Wootton Parkway, Suite 200, Rockville, MD 20852. Send one self-addressed adhesive label to assist that office in processing your request, or fax your request to 301–402–2071. See the SUPPLEMENTARY INFORMATION section for information on electronic access to the guidance document.

Submit written comments to COMMENTS ON SUBJECT WITHDRAWAL GUIDANCE, Office for Human Research Protections, 1101 Wootton Parkway, Suite 200, Rockville, MD 20852. Comments also may be sent via e-mail to *ohrp@hhs.gov* or via facsimile at 240–402–2071.

## FOR FURTHER INFORMATION CONTACT: Irene Stith-Coleman, PhD, Office for Human Research Protections, 1101 Wootton Parkway, Suite 200, Rockville, MD 20852, 240–453–6900; e-mail Irene.StithColeman@hhs.gov.

### SUPPLEMENTARY INFORMATION:

### I. Background

OHRP, Office of the Assistant Secretary for Health, is announcing the availability of a guidance document entitled, "Guidance on Withdrawal of Subjects From Research: Data Retention and Other Related Issues." The guidance document provides OHRP's first formal guidance on this topic. The document is intended primarily for IRBs, investigators, and funding agencies that may be responsible for the review or oversight of human subject research conducted or supported by HHS.

The guidance document applies to non-exempt human subjects research conducted or supported by HHS. The guidance addresses the following six topics:

(1) What does it mean when a subject withdraws from a research study?